Table 2.
Multivariable meta-regression of the selected predictors on BCG efficacy (R2 = 49.10%, n = 49).
| Moderators | Categories | RR (95% CI) | p-value (RE) |
|---|---|---|---|
| Revaccination | No | Reference | |
| Yes | 1.04 (0.79, 1.38) | 0.77 | |
| BCG route | Endobronchial | Reference | |
| Intramuscular | 2.16 (0.55, 8.50) | 0.27 | |
| Intratracheal | 1.01 (0.28, 3.67) | 0.99 | |
| Oral | 2.04 (0.75, 5.53) | 0.16 | |
| Subcutaneous | 1.46 (0.71, 3.00) | 0.3 | |
| Subcutaneous and Endobronchial | 1 (0.38, 2.66) | 1.00 | |
| Challenge method | Natural | Reference | |
| Experimental | 0.83 (0.40, 1.70) | 0.61 | |
| BCG source | Danish 1331 | Reference | |
| Danish freeze-dried | 1.14 (0.77, 1.68) | 0.51 | |
| Glaxo | 12.14 (1.52, 97.09) | 0.02 | |
| Pasteur 1173P2 | 0.98 (0.77, 1.23) | 0.84 | |
| BCG Dose | 0.68 (0.31, 1.51) | 0.35 | |
| Time from vaccination to challenge | 1.00 (0.99, 1.001) | 0.5 | |
| Length of exposure to challenge | 0.998 (0.997, 1) | 0.06 |